A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer

Harsh B. Pathak, Yan Zhou, Geetika Sethi, Jeff J. Hirst, Russell J. Schilder, Erica A. Golemis, Andrew K. Godwin

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

Molecular targeted therapies have been the focus of recent clinical trials for the treatment of patients with recurrent epithelial ovarian cancer (EOC). The majority have not fared well as monotherapies for improving survival of these patients. Poor bioavailability, lack of predictive biomarkers, and the presence of multiple survival pathways can all diminish the success of a targeted agent. Dasatinib is a tyrosine kinase inhibitor of the Src-family kinases (SFK) and in preclinical studies shown to have substantial activity in EOC. However, when evaluated in a phase 2 clinical trial for patients with recurrent or persistent EOC, it was found to have minimal activity.We hypothesized that synthetic lethality screens performed using a cogently designed siRNA library would identify second-site molecular targets that could synergize with SFK inhibition and improve dasatinib efficacy. Using a systematic approach, we performed primary siRNA screening using a library focused on 638 genes corresponding to a network centered on EGFR, HER2, and the SFK-scaffolding proteins BCAR1, NEDD9, and EFS to screen EOC cells in combination with dasatinib. We followed up with validation studies including deconvolution screening, quantitative PCR to confirm effective gene silencing, correlation of gene expression with dasatinib sensitivity, and assessment of the clinical relevance of hits using TCGA ovarian cancer data. A refined list of five candidates (CSNK2A1, DAG1, GRB2, PRKCE, and VAV1) was identified as showing the greatest potential for improving sensitivity to dasatinib in EOC. Of these, CSNK2A1, which codes for the catalytic alpha subunit of protein kinase CK2, was selected for additional evaluation. Synergistic activity of the clinically relevant inhibitor of CK2, CX-4945, with dasatinib in reducing cell proliferation and increasing apoptosis was observed across multiple EOC cell lines. This overall approach to improving drug efficacy can be applied to other targeted agents that have similarly shown poor clinical activity.

Original languageEnglish
Article numbere0144126
Pages (from-to)e0144126
JournalPLoS ONE
Volume10
Issue number12
DOIs
StatePublished - Dec 1 2015

Keywords

  • Antineoplastic Agents/pharmacology
  • Antineoplastic Combined Chemotherapy Protocols
  • Apoptosis
  • Carcinoma, Ovarian Epithelial
  • Casein Kinase II/antagonists & inhibitors
  • Cell Line, Tumor
  • Cell Proliferation/drug effects
  • Dasatinib/pharmacology
  • Drug Synergism
  • Dystroglycans/antagonists & inhibitors
  • Female
  • GRB2 Adaptor Protein/antagonists & inhibitors
  • Gene Library
  • Humans
  • Naphthyridines/pharmacology
  • Neoplasms, Glandular and Epithelial/drug therapy
  • Ovarian Neoplasms/drug therapy
  • Phenazines
  • Protein Kinase C-epsilon/antagonists & inhibitors
  • Proto-Oncogene Proteins c-vav/antagonists & inhibitors
  • RNA, Small Interfering/metabolism

Fingerprint

Dive into the research topics of 'A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer'. Together they form a unique fingerprint.

Cite this